• Akeso posted revenue of RMB 1.81 billion, up 27.92% year over year, driven mainly by cadonilimab and ivonescimab sales.
• Net loss narrowed to RMB 447.2 million from a year earlier, helped by a 4.24 percentage-point drop in selling expense intensity.
• Selling and marketing expenses rose to RMB 785.6 million, though fell to 43.56% of commercial sales revenue from 47.80%.
• R&D spending increased 7.12% to RMB 783.3 million as multiple programs remained in Phase III trials.
• Cash, cash equivalents, time deposits and financial products totaled RMB 9.16 billion; interest-bearing borrowings included RMB 974.7 million due within one year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260827-12303375), on August 27, 2026, and is solely responsible for the information contained therein.